（文章来源：证券日报） 证券日报网讯 2月24日，汉森制药在互动平台回答投资者提问时表示，截至2026年1月30日，公司含信 用账户合并股东名册的股东总数为22297户。 ...

Core Viewpoint - Hansen Pharmaceutical indicated that the revenue distribution for 2024 will be detailed in the annual report, with the Southwest region (including the Tibetan area) contributing 16.31% to the overall revenue, while the Tibetan area's contribution is relatively small [2] Group 1 - The company will provide details on the revenue distribution for 2025 in its future annual report [2] - The Southwest region's revenue contribution is significant, accounting for 16.31% of total revenue [2] - The Tibetan area's revenue contribution within the Southwest region is noted to be small [2]

经济观察网工业和信息化部等八部门联合印发《中药工业高质量发展实施方案(2026—2030年)》，明确 到2030年培育60个高标准中药原料生产基地、建设5个中药工业守正创新中心等目标，为中药行业带来 政策利好。该方案聚焦全产业链协同发展，有望推动汉森制药（002412）等企业受益于行业升级。 股票近期走势 近7个交易日(2026年2月6日至12日)，汉森制药股价呈现波动上涨态势。2月6日股价涨停，收盘报7.59 元，单日涨幅10.00%；2月9日股价继续上涨，收盘报8.02元，单日涨幅5.67%；2月10日股价震荡收平于 8.02元；随后两个交易日出现回调，2月12日最新股价为7.60元，较前一日下跌2.56%。区间累计涨幅达 10.14%，振幅22.46%。技术面上，MACD指标显示金叉信号，布林带突破上轨后进入震荡区间，短期 压力位关注7.89元。资金流向方面，2月12日主力资金净流出2725万元，散户资金净流入2936万元，需 关注资金面分化风险。 财报分析 机构观点 机构对汉森制药关注度较低，最新市场舆情偏中性。世纪证券报告指出，中药行业在政策引导下有望洗 牌，看好经典名方储备充足的企业。但当前机构评 ...

证券日报网讯2月11日，汉森制药（002412）在互动平台回答投资者提问时表示，公司(含全资子公司云 南永孜堂制药有限公司)针对肠胃功能改善方面的产品有四磨汤口服液、陈香露白露片、八味肉桂胶 囊、胃肠灵胶囊、通舒口爽胶囊和苦参胶囊。 ...

Group 1 - The A-share innovative drug sector is experiencing significant fluctuations and has become a core highlight in the pharmaceutical industry, with companies like Wanbangde and Haixiang Pharmaceutical hitting the daily limit up [1] - Multiple stocks, including Xinlitai and Hansen Pharmaceutical, are rising in tandem, indicating a dual-leader effect and a broader market rally within the sector [1] - Increased market attention and net capital inflow are evident, showcasing a clear upward trend and structural opportunities within the sector [1] Group 2 - A major strategic partnership has been established between Innovent Biologics and Eli Lilly, enhancing confidence in the sector and promoting the globalization of domestic innovative drugs [2] - The industry is projected to experience strong growth, with a significant increase in the number of approved domestic innovative drugs and market size by 2025, alongside record-high overseas licensing transactions [2] - Continuous policy support is evident, with the 2025 version of the medical insurance catalog adding several innovative drugs, addressing implementation challenges and providing a supportive framework for industry development [2] Group 3 - The innovative drug research and development sector is a core beneficiary of policy, technology, and globalization benefits, with companies like Wanbangde and Xinlitai directly benefiting from the industry's growth [3] - The pharmaceutical raw materials and CDMO sectors, represented by Haixiang Pharmaceutical, are also benefiting from the commercialization of innovative drugs, leading to increased demand [3] - The traditional Chinese medicine innovative drug sector is experiencing growth due to industry innovation and policy support, with companies like Hansen Pharmaceutical and Qianjin Pharmaceutical participating in the sector's upward trend [3]

Group 1 - The Chinese medicine sector experienced a short-term surge, with Hansen Pharmaceutical achieving two consecutive trading limits, and companies such as Guhang Medicine, China Resources Sanjiu, Guangdong Wannianqing, Biotech Valley, and Dong'e Ejiao also seeing gains [1] - The Chinese Medicine ETF (560080) recorded a transaction volume of 78.1084 million yuan [1] - The recent rise in the sector was influenced by the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 2026年2月9日，汉森制药（sz002412）触及涨停，涨停价8.35元，涨幅10.01%，总市值42.02亿元，流通 市值41.57亿元，截止发稿，总成交额5.55亿元。 根据喜娜AI异动分析，汉森制药涨停原因可能如下，公司治理优化+核心产品优势+现金流改善： 1、汉 森制药近期对公司章程及20余项管理制度进行修订，涵盖董事会运作、信息披露、关联交易等关键领 域，公司治理全面优化，规范性显著提升，信息披露透明度增强。其主导产品四磨汤口服液等为独家品 种，2023年营收占比达81.98%，核心产品竞争力强。 2、2025年三季度公司经营活动现金流同比增长 16.42%，达1.62亿元，现金流状况良好。同时控股股东质押比例从16.28%降至4.72%，显著降低股权质 押风险。国家药监局《中药注册管理专门规定》即将落地，公司主导产品已全部修订完毕，其他产品也 在有序推进，有望受益于行业整顿。 3、从市场表现来看，近期中药板块受政策等因素影响有一定热 度，部分中药股表现活跃。东方财富数据显示，当日中药板块有一定资金流入，形成板块联动效应。 4、技术面上，若该股MA ...

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Market Overview - As of January 26, the Shanghai Composite Index fell by 0.09%, closing at 4132.6052 points, while the Shenzhen Component Index decreased by 0.85%, closing at 14316.637 points [1] Top Gainers in Hunan Stocks - Hunan Gold opened at 25.270 and closed at 25.270, with a daily increase of 10.01%, reaching a high of 25.270 and a low of 25.270, with a trading volume of 79,635 lots [2] - Hunan Silver opened at 17.430 and closed at 18.080, with a daily increase of 9.98%, reaching a high of 18.080 and a low of 17.430, with a trading volume of 3,996,619 lots [2] - Tangrenshen opened at 4.300 and closed at 4.510, with a daily increase of 5.13%, reaching a high of 4.510 and a low of 4.250, with a trading volume of 1,047,088 lots [2] - *ST Gauss opened at 12.750 and closed at 12.730, with a daily increase of 4.86%, reaching a high of 12.750 and a low of 12.380, with a trading volume of 141,327 lots [2] - Hansen Pharmaceutical opened at 6.920 and closed at 7.050, with a daily increase of 2.17%, reaching a high of 7.170 and a low of 6.840, with a trading volume of 194,010 lots [2] Top Losers in Hunan Stocks - Hengli Tui opened at 0.160 and closed at 0.150, with a daily decrease of 11.76%, reaching a high of 0.170 and a low of 0.150, with a trading volume of 611,606 lots [3] - Mengjie Shares opened at 4.930 and closed at 4.580, with a daily decrease of 7.10%, reaching a high of 5.030 and a low of 4.530, with a trading volume of 504,009 lots [3] - Yuhuan CNC opened at 24.290 and closed at 22.770, with a daily decrease of 6.14%, reaching a high of 24.380 and a low of 22.600, with a trading volume of 84,859 lots [3] - Shanhe Intelligent opened at 12.750 and closed at 12.120, with a daily decrease of 4.57%, reaching a high of 12.750 and a low of 12.020, with a trading volume of 579,723 lots [3] - Changlan Technology opened at 22.850 and closed at 22.050, with a daily decrease of 4.46%, reaching a high of 22.900 and a low of 21.900, with a trading volume of 152,679 lots [3]

Group 1 - The core function of Bai Bei Yi Lung Capsules is to nourish the lungs, relieve cough, and resolve phlegm, specifically for treating cough due to lung yin deficiency and chronic bronchitis cough [1]